PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while AGEN shows 20262.42% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-105.80%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-105.80%
Both companies reducing total costs. Martin Whitman would check industry trends.
-50.00%
Both companies reducing interest expense. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
94.20%
EBITDA growth exceeding 1.5x AGEN's 31.30%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
94.20%
Operating income growth exceeding 1.5x AGEN's 27.52%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while AGEN shows 38192.12% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-94.81%
Tax expense reduction while AGEN shows 39484.43% growth. Joel Greenblatt would examine advantage.
94.81%
Net income growth exceeding 1.5x AGEN's 24.62%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
98.22%
EPS growth exceeding 1.5x AGEN's 24.50%. David Dodd would verify competitive advantages.
98.22%
Diluted EPS growth exceeding 1.5x AGEN's 24.50%. David Dodd would verify competitive advantages.
200.00%
Share count reduction below 50% of AGEN's 0.20%. Michael Burry would check for concerns.
200.00%
Diluted share change of 200.00% while AGEN is stable. Bruce Berkowitz would verify approach.